Arvinas, Inc. (ARVN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.39+0.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ARVN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||
| Revenues | 316.7 | 262.6 | 263.4 | 78.5 | 131.4 | 53.6 | 25.9 | 43.0 | 14.3 |
| Total Revenues | — | 262.6 | 263.4 | 78.5 | 131.4 | 53.6 | 25.9 | 43.0 | 14.3 |
| Operating Expenses & Income | |||||||||
| R&D Expenses | 238.7 | 285.2 | 348.2 | 379.7 | 315.0 | 180.4 | 108.4 | 67.2 | 45.2 |
| Operating Income | (18.1) | (118.5) | (250.2) | (401.5) | (263.2) | (188.4) | (120.8) | (51.5) | (43.8) |
| Earnings from Continuing Operations | |||||||||
| Interest Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 |
| Interest & Investment Income | 28.3 | 38.4 | 54.8 | 38.8 | 12.0 | 1.8 | 3.5 | 4.6 | 2.5 |
| Net Interest Expenses | — | — | — | (38.8) | (12.0) | (1.8) | (3.4) | (4.5) | (2.4) |
| Other Non-Operating Income / Expenses | 28.1 | 38.0 | 51.9 | 37.6 | 12.2 | 4.3 | 5.6 | 5.9 | 2.3 |
| EBT, Incl. Unusual Items | — | (80.5) | (198.3) | (363.9) | (251.0) | (184.1) | (115.2) | — | — |
| Income Tax Expense | 0.7 | 0.3 | 0.6 | 0.9 | 20.9 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||||
| Net Income | 9.1 | (80.8) | (198.9) | (367.0) | (283.0) | (191.0) | (119.3) | (70.3) | (41.5) |
| Per Share | |||||||||
| Basic EPS | 0.14 | (1.14) | (2.77) | (6.62) | (5.31) | (3.82) | (3.02) | — | — |
| Diluted EPS | 0.14 | (1.14) | (2.77) | (6.62) | (5.31) | (3.82) | (3.02) | — | — |
| Revenue per Share | 4.82 | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 64.8 | 70.9 | 71.9 | 55.5 | 53.2 | 50.0 | 39.5 | — | — |
| Diluted Weighted Avg Shares | 65.7 | 70.9 | 71.9 | 55.5 | 53.2 | 50.0 | 39.5 | — | — |
| Supplemental | |||||||||
| EBITDA | — | (115.5) | (245.6) | (396.7) | (256.9) | (183.6) | (117.6) | (49.9) | (43.1) |
| EBIT | (18.1) | (118.5) | (250.2) | (401.5) | (263.2) | (188.4) | (120.8) | (51.5) | (43.8) |
| Effective Tax Rate | — | — | — | -0.2% | -8.3% | 0.0% | 0.0% | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.